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Abstract: Rotavirus infection is the most common cause of severe gastroenteritis globally, 
with greater than 86% of deaths occurring in low-income and middle-income countries. 
There are two rotavirus vaccines currently licensed in the United States and prequalified by 
the World Health Organization. RV1 is a monovalent attenuated human rotavirus strain, given 
orally in two doses. RV5 is a pentavalent human-bovine reassortant rotavirus vaccine, given 
orally in three doses. A third rotavirus vaccine, LLV , is a lamb rotavirus strain given orally 
as a single dose, which is currently available only in China. RV1 and RV5 have been shown 
to be highly efficacious in developed countries, and initial results from trials in Africa and 
Asia are promising as well. At least three other vaccines are in development, which are being 
developed by manufacturers of developing countries. Further studies are needed to clarify 
issues including administration of oral rotavirus vaccines with breastfeeding and other oral 
vaccines, and alterations in dosing schedule. Using new data on global diarrheal burden, rota-
virus is estimated to cause 390,000 deaths in children younger than 5 years. Should rotavirus 
vaccines be introduced in the routine immunization programs of all countries, a potential of 
170,000 deaths could be prevented annually. The largest impact on mortality would be seen 
in low-income and middle-income countries, despite poor immunization coverage and lower 
efficacy. Therefore, international efforts are needed to ensure that rotavirus vaccines reach the 
populations with highest burden of rotavirus disease.
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Introduction
epidemiology
Rotavirus infection is the most common cause of severe diarrhea globally, resulting in 
an estimated 114 million episodes of gastroenteritis, 24 million outpatient visits, and 
2.4 million hospitalizations each year.1 In total, there were over 500,000 deaths attrib-
uted to rotavirus in 2004, resulting in 5% of all deaths in children ,5 years of age.2,3 
The rate of rotavirus illness is similar in both developed and developing countries; in 
all settings, rotavirus is responsible for approximately 39% of hospitalizations due to 
diarrhea regardless of a country’s income status.4 However, the burden of mortality is 
almost entirely in developing countries where access to care is limited and risk factors for 
disease are high. Every year, greater than 86% of deaths occur in Asia and sub-Saharan 
Africa, whereas less than 1,000 rotavirus deaths occur in high-income countries.3
Rotavirus gastroenteritis occurs almost exclusively in infants and children, with 
nearly every child having been infected by the age of 5 years.5 The majority of serious 
infections occur between 4 and 24 months of age, although the peak age of serious Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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disease varies globally.6 In developing countries, the mean 
age of symptomatic rotavirus infection is between 6 and 
9 months while industrialized countries have a median age 
between 9 and 15 months.7 Older children are protected from 
serious disease by previous exposure and apparent infection: 
if it occurs, it is usually mild.8   Similarly, disease can occur 
in neonates but is typically mild or asymptomatic due to 
protection from maternal antibodies.5,9   Rotavirus infection 
shows strong seasonal variation; in temperate high-income 
countries, rotavirus disease occurs most often during the 
winter, whereas seasonality is less pronounced in tropical 
and low-income countries.7
Biology
Rotaviruses are nonenveloped viruses of the genus   Reoviridae.10 
The virus is characterized by a double-stranded RNA genome 
composed of 11 segments, which encode for six structural 
and six nonstructural proteins.10,11 Rotavirus particles are 
icosahedrons, 70–75 nm in diameter, composed of three con-
centric layers of structural proteins: the core, an inner capsid, 
and an outer capsid. The outer capsid is composed of a VP7 
coating with VP4 spikes protruding from the viral surface.11 
This layer is the most antigenically important portion of the 
virus, with the VP7 glycoprotein (G-type antigen) and VP4 
protease-sensitive protein (P-type antigen) being the major 
immunological targets of the human immune system.11 The 
inner capsid is composed solely of VP6. Based on the antigenic 
properties of VP6, rotaviruses are broken into 7 serogroups, 
denoted A–G. Serogroup A is the only serogroup that com-
monly causes human disease.10,12 Conventionally, rotavirus 
strains are denoted by the P serotype name first, followed by 
its genotype in brackets, followed by the G-type.13
Serotype variation
Evolutionary pressures have led to a diversity of VP4 and 
VP7, resulting in over 19 G types, 28 [P] types, and over 
40 G and P antigen combinations observed in human   disease 
(Table 1).11,12 Globally, six G + P combinations (P[8]G1, P[4]
G2, P[8]G3, P[8]G4, P[8]G9, and P[6]G9) account for .80% 
of rotavirus disease in all regions with the exception of 
Africa.12 Prior to vaccine introduction, P[8]G1 was the most 
common strain globally, accounting for 72%–82% of all 
rotavirus disease in North America, Europe, and   Oceania and 
for 23%–34% of strains isolated in South America, Asia, and 
Africa.12 Currently, P types 4, 6, 8, and 9 account for .95% of 
disease regardless of region. More diversity exists in G-type, 
with 1–4, 8, and 9 accounting for .95% of disease. Notably, 
genotype distribution is not constant in any region; substantial 
variation occurs over time and within countries.14,15
Transmission and pathogeneses
Rotavirus is believed to be transmitted via the fecal oral route, 
close personal contact, and contact with contaminated envi-
ronmental sources. However, the prevalence of rotavirus in 
high-income countries despite improved sanitation suggests 
that nonfecal routes play a role in transmission. Rotavirus has 
been identified being shed from the oropharynx of children 
with symptoms of upper respiratory track disease, both with 
and without apparent gastrointestinal disease;16 respiratory 
droplets may be an important source of transmission.17,18
Upon ingestion, the rotavirus targets the epithelial lining 
of the intestine.11 During viral replication, the segments of 
the viral genome are disassociated from viral proteins and 
one another; this allows reassortment of genotypes in cells 
infected with more than one strain of rotavirus.19 Rotavi-
rus disrupts the normal functioning of the gastrointestinal 
mucosa through a number of mechanisms;11 the most potent 
is the viral enterotoxin NSP4, which alters the permeability 
of the gut mucosa by weakening the tight junctions between 
cells, disrupting the cytoskeleton of the infected cells, 
increasing the secretion of chlorine ions, and stimulating 
the gut motility through the enteric nervous system.20 This 
Table 1 Regional distribution of rotavirus serotypes
Serotype Africa, % Asia, % Europe, % North 
America, %
Oceania, % South  
America, %
P[8]G1 23 34 72 73 82 34
P[4]G2 2 13 9 11 13 23
P[8]G3 21 1 2 6 1 2
P[8]G4 4 20 11 1 2 9
P[8]G9 5 5 3 1 1 15
P[6]G9 2 7 1 2 0 1
Other 16 6 1 1 0 5
Unusual 27 14 1 5 0 11
Note: Copyright © 2005. Adapted with permission from Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development 
and implementation of an effective rotavirus vaccine. Rev Med Virol. 2005;15:29–56.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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causes in an uncontrolled outflux of water into the intestinal 
lumen, resulting in profuse diarrhea.
Clinical disease
Rotavirus disease is most commonly characterized by acute 
gastroenteritis. After an incubation period of 1–3 days,5 
rotavirus infections present with symptoms common to many 
enteric pathogens: profuse watery diarrhea, vomiting, and 
fever.21 The severity of symptoms varies but on average is 
more severe than other viral enteric pathogens;5,22 although 
rotavirus only accounts for 6%–8% of community diarrhea 
cases, it accounts for 25%–40% of diarrheal cases requiring 
hospitalization.6 Rotavirus infections are not invasive and do 
not elicit a destructive inflammatory response; as a result, 
dysentery does not occur with rotavirus infections. Diarrhea 
typically lasts from 4 to 7 days.19 Virus-specific diagnostic 
tests and treatment are not necessary as symptoms typically 
resolve within a week of disease onset.23 However, supportive 
care, primarily rapid rehydration, is critical to preventing 
complications.
Complications
The most common complication associated with rotavirus 
infection is dehydration. The symptoms of mild and moderate 
dehydration, not specific to rotavirus, are restlessness, irrita-
bility, decreased skin turgor, sunken fontanelle (in infants), 
sunken eyes, and thirst.24 Severe dehydration is characterized 
by reduced or altered consciousness, lack of urine output, low 
blood pressure, weak quickened pulse, cool moist extremities, 
and peripheral cyanosis.25
Malnutrition and diarrhea form a destructive cycle 
in   children and as the most common diarrheal pathogen 
in infants, rotavirus plays an important role in this cycle. 
  Malnutrition increases the susceptibility of children to future 
gastrointestinal infections, and diarrhea disrupts the gut’s 
ability to absorb nutrients, leading to an exasperation of 
malnutrition. As a result, 61% of children who die of diarrhea 
have malnutrition as an underlying risk factor.26 Furthermore, 
malnutrition caused by diarrhea leads to significant physical 
and mental growth shortfalls that negatively affect children 
throughout their lives,27 including negative impacts on school 
performance.28,29 Nutritional support is a critical component 
of ameliorating the short-term and long-term consequences 
of rotaviral, as well as other diarrhea diseases.
Treatment
Dehydration is responsible for .90% of deaths from infectious 
diarrhea.30 Treatment for rotavirus gastroenteritis, as with the 
majority of infectious watery diarrhea, is supportive; children 
should receive appropriate hydration and nutritional support. 
Since the 1970s, the World Health Organization (WHO) has 
recommended the use of oral rehydration solution (ORS) for 
the treatment of dehydration; the worldwide extensive use 
of this solution saved millions of lives. In the early 1990s, 
multiple laboratory and clinical studies showed that reducing 
the osmolarity of ORS resulted in increased intestinal water 
absorption compared with standard ORS. A meta-analysis of 
trials of low-osmolarity ORS for acute diarrhea in children 
found that there was a 20% reduction in stool output, a 30% 
reduction in vomiting, and nearly a 40% reduction in the need 
for unscheduled intravenous treatment in patients receiving 
the low-osmolarity ORS compared with those receiving 
original ORS.31 The current WHO recommendation is for 
low-osmolarity ORS (245 mOsm/L) with 75 mmol/L each 
of sodium and glucose. In cases of severe dehydration in 
which the child is obtunded or unable to drink, intravenous 
or intraosseous fluids should be used for initial management, 
with the institution of ORS as soon as possible.
Until the 1970s, the medical community endorsed the 
belief that feeding should be withheld during diarrhea in order 
to “rest the gut”. In the 1980s, a series of studies demonstrated 
that continued feeding during a diarrheal episode is safe and 
improves outcome.32–37 Based on these studies, the WHO 
incorporated early refeeding into their recommendations for 
diarrhea treatment.38
Deficiency of zinc can result in diminished immune 
response and healing. Although the role of zinc supplementa-
tion in rotavirus diarrhea has not been evaluated separately, 
studies in developing countries have shown that zinc supple-
mentation, when given in addition to ORS, is highly effective in 
decreasing the duration and severity of diarrheal episodes.39–41 
Administration of zinc along with ORS led to a decrease 
in hospitalizations for diarrhea, as well as other   illnesses, 
in two large-scale studies.42,43 In Bangladesh, Baqui et al42 
reported a 24% reduction in the diarrhea hospitalization rate 
(95% confidence interval [CI]: 0.59–0.96) and resulted in 
an overall decrease in mortality (risk ratio = 0.49; 95% CI: 
0.25–0.94). Therefore, in developing country settings, the 
WHO recommends the daily use of zinc supplementation for 
10–14 days with every episode of acute diarrhea.
Antimicrobial therapy should be used only in specific 
cases of infectious diarrhea and in general do not have a 
role in the treatment of rotavirus gastroenteritis. Probiotics, 
microorganisms believed to restore microbial balance in the 
gastrointestinal tract, may have a role in the treatment of 
diarrhea by enhancing the immune response or   providing Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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a competitive blockage of pathogen receptor sites. In a 
meta-analysis of seven clinical trials, Lactobacillus GG 
(LGG) was shown to reduce the duration of rotavirus diarrhea 
by 2.1 days (95% CI: 3.6–0.6);44 however, a recent trial in 
rural India did not show any efficacy.45 Saccharomyces bou-
lardii and Lactobacillus reuteri have also shown beneficial 
effects for rotavirus gastroenteritis.46 Additional studies are 
needed to further define the necessary dose and duration of 
treatment, particularly in developing country settings.
Several over-the-counter and prescription   antimotility 
(eg, loperamide), antisecretory (eg, racecadotril), and 
toxin-binding agents (eg, cholestyramine) are available for 
symptomatic relief of diarrhea.47–49 Because of the limited evi-
dence and uncertain side-effect profiles, most experts do not 
recommend the use of these agents, particularly for pediatric 
patients.50,51 Nitazoxanide, an antiprotazoal/  antihelminthic 
drug, was shown to reduce the duration of rotavirus diar-
rhea from 75 hours in the placebo group to 31 hours in 
the intervention group (P = 0.0137) in an Egyptian trial of 
children hospitalized with severe rotavirus gastroenteritis.52 
A more recent single-blind trial in Bolivia also showed that 
duration of diarrhea was reduced from 79 hours to 54 hours 
(P = 0.009) with nitazoxanide.53 Further studies will be 
needed to fully evaluate the safety and efficacy of nitazox-
anide as a treatment for rotavirus gastroenteritis.
Although the morbidity and mortality from rotavirus 
gastroenteritis differ across socioeconomic strata, rates of 
illness are similar across developed and developing country 
settings. This indicates that hygiene and sanitation improve-
ments, which have been credited with reducing incidence of 
most causes of infectious diarrhea in developed countries, are 
unlikely to prevent rotavirus disease significantly.2 Therefore, 
prevention in the form of vaccines is essential for the control 
of rotavirus disease.
Rotavirus vaccines
Biological basis of vaccinology
Protection against rotavirus infection has been associ-
ated with the presence of antirotavirus IgA antibodies 
in the gastrointestinal mucosal surface.54 Although the 
IgA response is often used to measure vaccine immune 
response, levels of serum rotavirus IgA antibody do not 
always correlate with levels of IgA antibody in the gut.13 
Presence of virus-specific IgA in feces or serum was not 
predictive of protection against disease in studies of the 
simian – human reassortant vaccine. Therefore, it remains 
difficult to identify the best immune correlate of protection 
from a rotavirus vaccine.
It is also unclear how many serotypes a rotavirus   vaccine 
should contain. Although initial infection does not confer 
complete immunity to rotavirus, clinical studies show that 
primary infection does seem to protect against severe disease 
upon reinfection. For example, one study in West Africa 
showed that primary infection conferred 70% (95% CI: 
29–87) protection against subsequent rotavirus diarrhea.55 
Similarly, although neonatal infection does not confer com-
plete protection against disease in future, children who had 
rotavirus infection as neonates appear to have less-severe 
disease later in childhood. This protection does not appear 
to be strain specific, that is, children who were infected by 
one rotavirus strain as neonates had less-severe diarrhea later 
in childhood even when infected with a different strain.56 
However, protection is stronger when a child is exposed to a 
G-type with which they have been previously infected.57 When 
measuring immunologic response to natural rotavirus infec-
tion, it appears that the antibody response is higher against 
the infecting G-type than against other G-types.58 The benefits 
of a multiserotype vaccine vs a single-serotype approach to 
vaccine development have not been established.
Several studies have evaluated animal strain vaccine 
candidates, with inconsistent results. The RIT4237 bovine 
strain was isolated from a calf and attenuated in cell culture, 
and found to be immunogenic by serum immunoglobulin 
response in human infants.59 Although initial efficacy trials 
in Finland appeared positive, subsequent studies showed 
little or no protection against rotavirus disease.60–62 The 
bovine strain WC3 was isolated from a calf in Pennsylvania 
in 1981. This strain alone as a vaccine was not consistently 
protective in all efficacy trials, with protection ranging 
from ,10% to 76.1%.63 A third strain was the rhesus rota-
virus vaccine (RRV), which was isolated from a monkey and 
also attenuated in cell culture. Similar to RIT4237, while 
initial efficacy studies showed a modest level of protection, 
subsequent studies showed little to no effect.62,64
The poor results seen when using single-animal rotavirus 
strains as human vaccine candidates lead to the development 
of two major categories of rotavirus candidate vaccines: 
attenuated human rotavirus strains and recombinant (reas-
sortant) rotaviruses containing human and animal rotavirus 
components. Attenuated human rotavirus strains are produced 
by serial passage of rotavirus strains isolated from humans 
in cell culture to reduce their pathogenicity. Reassortant 
rotavirus vaccines take advantage of the segmented rotavirus 
genome to create viruses that combine the RNA-encoding 
VP7 proteins from a human rotavirus with the remaining 
RNA segments of an animal rotavirus. The goal was to Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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invoke the immune response to a G-type antigen from a 
human virus. Reassortants were initially created by coinfect-
ing a monkey with bovine and human rotavirus and allow-
ing the gene reassortant to occur by chance. Subsequent 
reassortants were created in laboratories and propagated 
in Vero cells.13
RRv-Tv
A quadrivalent human – animal reassortant vaccine (RRV-TV) 
containing serotypes G1, G2, G3, and G4 was developed by 
the National Institutes of Health and Wyeth Laboratories 
(Wyeth Laboratories, Monmouth Junction, NJ). The vac-
cine contained the RRV strain and three simian – human 
reassortant strains. Several different doses were tested for 
safety, immunogenicity, and efficacy. In the two trials done 
in the United States, the dose containing 105 plaque-forming 
units per strain had an efficacy against all rotavirus disease of 
49% (95% CI: 31–63) and 57% (95% CI: 26–67) and against 
severe rotavirus disease of 80% (95% CI: 56–91) and 82% 
(95% CI: 29–88).62,65 There was some concern about the 
efficacy of the vaccine in developing countries; the higher 
dose vaccine when tested in Venezuela had an efficacy of 48% 
(95% CI: 33–61) against all rotavirus disease and 88% (95% 
CI: 61–96) against severe rotavirus disease, which was similar 
to the results found in the United States.66 The vaccine was 
licensed in the United States in 1998 under the trade name 
Rotashield (Wyeth Lederle, Philadelphia, PA).
After several cases of intussusception were reported via 
the US Vaccine Adverse Event Reporting System (VAERS), 
a case – control investigation was conducted in 429 infants 
with intussusception and 1,763 matched controls. An 
increased risk of intussusception 3–14 days after the first 
dose was found (adjusted odds ratio [OR] = 21.7, 95% CI: 
9.6–48.9).67 Intussusception is not a known consequence of 
natural rotavirus infection. The possible explanations of why 
RRV-TV might cause intussusception include the following: 
(1) one strain in the vaccine may have been pathogenically 
unique from wild-type rotavirus, (2) the vaccine virus may 
be absorbed in the intestine in a different manner than wild 
type, and 3) the immune response induced by the vaccine 
strain might be different.13 Although the actual mechanism 
of the relationship between RRV-TV and intussusception is 
not clear, the simian strain RRV is considered the most likely 
causative vaccine strain. Following the results of this analysis, 
the use of the vaccine was discontinued. This vaccine was 
subsequently withdrawn from the market, and assessing the 
risk of intussusception has remained a key component of all 
subsequent rotavirus trials.
Rv5
The oral human-bovine pentavalent reassortant rotavirus 
vaccine (Rotateq®; Merck and Co., Whitehouse Station, NJ) 
consists of 5 human-bovine reassortants suspended in a fully 
liquid buffer-stabilized formulation (RV5). The vaccine is 
based on the creation of a new rotavirus strain that contains a 
single human virus coat protein on the viral surface, with the 
rest of the structural proteins from a bovine strain (WC3).
Candidate reassortants were created in vitro by coinfect-
ing cells with WC3 and a human rotavirus strain. The progeny 
containing the appropriate strain mixture is selected using 
molecular and immunologic selection. The human-bovine 
reassortants for this vaccine were initially cultured using 
the monkey cell line MA104, and then propagated in the 
commonly used monkey cell line Vero using standard cell-
culture technique for production. The five human serotypes 
contained in the vaccine are G1, G2, G3, G4, and P1A[8]. 
The reassortant viruses with G1–G4 express the attachment 
protein P7[5] from the bovine strain. The reassortant virus 
expresses the attachment protein P1A[8] from the human 
strain and the outer capsid protein G6 from the bovine strain.68 
A comparison of three different potencies of the RV5 vaccine 
for safety, immunogenicity, and efficacy was conducted in 
Finnish infants aged 2–8 months from 1998 to 2001.14 Efficacy 
estimates for gastroenteritis of any severity in the first year 
following vaccination were 68.0% (95% CI: 31.1–86.4), 
74.3% (95% CI: 37.9–91.0), and 57.6% (95% CI: 11.8–80.9) 
in the high-potency, middle-potency, and low-potency groups, 
respectively; the middle-potency vaccine was chosen for the 
subsequent phase III efficacy trials.
Subsequently, clinical trials and postintroduction studies 
have demonstrated the efficacy of three doses of vaccine given 
with routine infant immunizations (Figure 1). From 2001 
to 2004, the Rotavirus Efficacy and Safety Trial (REST), 
a double-blind, placebo-controlled, randomized trial, was 
conducted in over 68,000 infants in 11 countries.69 In an 
immunogenicity study in a small subset of the children, 
seroconversion rates for serum antirotavirus IgA were 95.2% 
(95% CI: 91.2–97.8) in 189 vaccine recipients and 14.3% 
(95% CI: 9.3–20.7) in 161 placebo recipients. In the per-
protocol efficacy analysis, among 4,512 subjects, vaccine 
efficacy against G1–G4 gastroenteritis of any severity was 
74% (95% CI: 66.8–79.9) and 98% (95% CI: 88.3–100) 
for severe disease in the first rotavirus season. Vaccine effi-
cacy in the second season of RV gastroenteritis was 62.6% 
(95% CI: 44.3–75.4) against any disease and 88% (95% CI: 
49.4–98.7) against severe disease. Efficacy has been shown 
across several regions. In fully vaccinated infants in the Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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REST trial, reductions in RV-associated hospitalizations and 
emergency department visits up to 2 years after vaccination 
were 94.7% (95% CI: 90.9–96.9) in Europe, 94.9% (95% 
CI: 84.0–98.9) in the United States, and 90.0% (95% CI: 
29.4–99.8) in Latin America/Caribbean.70
More recently, efficacy trials were implemented in 
Kenya, Ghana, Mali, Bangladesh, and Vietnam to determine 
the protection in lower income settings, with results now 
available for the first year of follow-up (Figure 1). Prelimi-
nary results from the efficacy trials in Africa (Kenya, Ghana, 
Mali) show a three-dose efficacy of 64% (95% CI, 40–79) 
against severe rotavirus gastroenteritis. In Asia (Bangladesh 
and Vietnam), a three-dose efficacy of 51% (95% CI, 13–73) 
has been shown against severe rotavirus gastroenteritis.71 
Safety and   immunogenicity have also been demonstrated 
in Taiwan.72
Since its introduction in the United States in 2006, 
RV5 has had a dramatic impact on rotaviral disease. 
Postintroduction surveillance data from the Centers for 
Disease Control and Prevention (CDC) in the United States 
for the 2007–2008 and 2008–2009 seasons compared with 
the prevaccination period showed that the rotavirus seasons 
were reduced from 26 weeks to 14–17 weeks, and the peak 
percentage of rotavirus positive tests reduced from 43% 
to 17%–25%.73 An evaluation of children in the United 
States vaccinated in the first two seasons after licensure 
compared with an unvaccinated cohort showed a vaccine 
efficacy of 100% (95% CI: 76–100) against rotavirus 
  gastroenteritis hospitalizations and emergency department 
visits.74 A case – control study in Texas showed a three-dose 
vaccine efficacy of 100% (95% CI: 71–100) against severe 
rotavirus gastroenteritis requiring hospitalization. Vaccine 
effectiveness of one and two doses against hospitalization 
and emergency department visits was 69% (95% CI: 13–89) 
and 81% (95% CI: 13–96),   respectively.75 In addition, RV5 
has also shown promise in low-income settings. A postintro-
duction evaluation in Nicaragua showed a three-dose efficacy 
of 58% (95% CI: 30–74) against severe rotavirus diarrhoea.76 
In the 2007 rotavirus season, despite a vaccination coverage 
of approximately 26%, hospitalizations and outpatient visits 
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Figure 1 Comparison of vaccine efficacy and effectiveness estimations from clinical trials of RV1 and RV5 against any serotype severe rotavirus gastroenteritis, stratified 
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for diarrheal illness declined by 11% and 23%, respectively, 
compared with prevaccination years.77
Due to the safety concerns associated with rotavirus 
  vaccines, enhanced monitoring for possible vaccine-  associated 
episodes of intussusceptions and other adverse effects is ongo-
ing in many countries. The CDC published reports of postmar-
keting surveillance of intussusception after RV5   vaccination 
through September 25th, 2007. Under the assumptions that 
100% of distributed doses were given and 100% of cases of 
intussusception were reported, the number of cases of intus-
susception reported through VAERS were lower than what 
would have been expected for the age-adjusted baseline rates 
at 1–7 days after vaccination (relative risk [RR] = 0.51; 95% 
CI: 0.32–0.81) or at 1–21 days after vaccination (RR = 0.30; 
95% CI: 0.20–0.44). The Vaccine Safety Datalink (VSD), 
encompassing persons enrolled in 8 large health maintenance 
organizations, is also being used to monitor intussusception 
risk post vaccination. As of May 31st, 2008, 207, 621 doses 
of RV5 had been administered to infants in VSD-associated 
health management organizations; a total of five cases of 
intussusception were observed in children who had received 
all doses compared with an expected number of 6.75 episodes 
(RR = 0.74).78
Rv1
The rotavirus vaccine RV1 (Rotarix; GlaxoSmithKline, 
Genval, Belgium) is a monovalent vaccine composed of an 
attenuated human rotavirus strain G1P[8]. This parent strain 
was isolated during a clinical trial of an early rotavirus vac-
cine in 1988.2 Although the vaccine tested in this study was 
eventually found to be ineffective, observation over subse-
quent years showed that children infected with the naturally 
circulating strain during the clinical trial were protected 
against 81% of subsequent rotavirus infections and 100% 
protected against severe rotavirus disease. In addition, serum 
antibodies produced during infection were able to neutralize 
G types 1–4.79
An isolate of this strain, denoted 89–12, was serially 
passed in tissue culture, resulting in an attenuated viral 
strain that was subsequently used in clinical trials.2 Phase I 
and II clinical trials in Europe, the United States, and Latin 
America demonstrated excellent safety, immunogenicity, and 
efficacy.80 Early clinical trials showed an efficacy of 89% 
(95% CI: 65.4–94.5) after two doses of vaccine resulting in 
adoption of the two-dose schedule.81,82
Subsequent large randomized, double-blind, placebo-
controlled phase three clinical trials have demonstrated the 
efficacy of the vaccine given with the first and second dose 
of routine infant vaccination (Figure 1). A study in Finland 
and 11 Latin American countries following 20,169 vaccine 
and placebo recipients for 9–10 months, following comple-
tion of the two-dose series, found an 85% reduction (95% 
CI: 71.7–92.4) in severe rotavirus gastroenteritis and a 42% 
(95% CI: 29–53) reduction in hospitalization for all-cause 
gastroenteritis.83 Subsequent follow-up in Finland showed 
no reduced protection during the second rotavirus season.84 
A similar but smaller trial of 3,994 infants in six European 
countries demonstrated efficacy across two subsequent 
  rotavirus seasons.85 During the first rotavirus season, the 
vaccine recipients has 87.1% (95% CI: 79.6–92.1) fewer 
rotavirus episodes and 95.8% (95% CI: 89.6–98.7) fewer 
severe rotavirus episodes. During the second season, the effi-
cacy dropped slightly to 71.9% (95% CI: 61.2–79.8) against 
any rotavirus gastroenteritis and 85.6% (95% CI: 75.8–91.9) 
against severe rotavirus disease. A study in Hong Kong,   
Singapore, and Taiwan following 10,708 children until 24 
months of age found higher efficacy, noting a 96.1% (95% 
CI: 85.1–99.5) reduction in severe rotavirus gastroenteritis 
and 30.3% (95% CI: 13.1–44.2) against reporting one or more 
episodes of severe all-cause gastroenteritis.86
To assess RV1 efficacy in low-income countries, a ran-
domized trial was conducted in 3,166 South African and 
1,773 Malawian infants.87 In South Africa, the overall effi-
cacy was similar to what was seen in high-income country 
settings, with the vaccine recipients having 76.9% (95% CI: 
56.0–88.4) fewer cases of severe rotavirus gastroenteritis 
and 44.1% (95% CI: 19.8–61.0) lower incidence of all-cause 
severe gastroenteritis. However, in Malawian children, the 
efficacy of the vaccine was reduced, preventing only 49.4% 
(95% CI: 19.2–68.3) of severe rotavirus gastroenteritis. This 
difference could not be explained by serotype differences, 
as both populations showed similar efficacy against G1 and 
non-G1 serotypes. Interestingly, despite the reduced effi-
cacy, more disease was prevented per recipient in Malawi 
than in South Africa due to the higher burden of disease. In 
Malawi, vaccine prevented 3.9 episodes of severe rotavirus 
gastroenteritis per 100 vaccinated children compared with 
preventing 2.5 episodes per 100 vaccinated children in South 
Africa.88 In addition, the study compared two- and three-dose 
schedules of RV1, with vaccine given at 6, 10, and 14 weeks 
or 10 and 14 weeks. No statistical difference was found in 
the efficacy of the vaccine in children who received two 
versus three doses.
RV1 has demonstrated efficacy against vaccine serotype 
and nonvaccine serotype diseases. In Finland and Latin 
America, RV1 showed serotype-specific efficacy for G1P[8] Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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of 91.8% (95% CI: 74.1–98.4) and a combined efficacy 
against G3P[8], G4P[8], and G9P[8] of 87.3% (95% CI: 
64.1–96.7).83 Too few cases of non-G1 or P[8] serotypes 
were isolated to determine efficacy against these groups. In 
Europe, the highest efficacy was seen against G1 serotypes, 
with the vaccine preventing 89.8% (95% CI: 82.9–94.2) of 
any severe gastroenteritis.85 In Asia, RV1 prevented 100% 
(95% CI: 80.8–100) of G1 serotypes and 93.6% (95% CI: 
74.7–99.3) of non-G1 serotypes of severe gastroenteritis.86 
Several Brazilian studies have shown efficacy against non-
vaccine serotypes.89,90 Among these, a case control study 
comparing children hospitalized with G2P[4] rotavirus gas-
troenteritis to those hospitalized with acute respiratory infec-
tions demonstrated an efficacy of 77% (95% CI: 43–90) in 
infants aged 6–11 months.90 However, the efficacy dropped to 
15% (95% CI: −101 to 64) in children older than 12 months. 
Further studies are needed to establish the efficacy of RV1 
against serotypes that are neither G1 nor P[8].
Postintroduction impact of RV1 has been demonstrated 
in several countries.91–93 A retrospective case – control study 
in indigenous Australians during an outbreak of G9P[8] 
rotavirus found RV1 to be 84.5% (95% CI: 23.4–96.9) 
effective at preventing hospitalized rotavirus infections.92 
RV1 was introduced to the national immunization system 
in Brazil in 2006, with a vaccination coverage of 46.5% in 
2006 and 78.3% in 2007.91 In 2006, there were 26% fewer 
hospitalizations in children aged younger than 1 year due to 
gastroenteritis compared with the average number of yearly 
hospitalizations from 1998 to 2005. In 2007, the hospital-
ization reduction was 48% compared with prevaccination 
levels. In 2007, a decrease in all-cause diarrheal disease 
was seen in children aged 1–5 years, reversing an increas-
ing trend in gastroenteritis in this age group that had been 
seen in the past 10 years. Mexico introduced RV1 in 2007. 
In 2008, the incidence of diarrhea-related deaths decreased 
to 11.8 per 100,000 children younger than 5 years compared 
with 2003–2006 with an average of 18.1 deaths per 100,000 
children; a rate reduction of 35% (95% CI: 29–39). This 
reduction continued though the 2009 rotavirus season. Such 
a dramatic reduction in diarrhea mortality is very promising 
for reducing mortality due to rotavirus infections.
Due to the previous association of rotavirus vaccination 
with intussusception, an extended intensive follow-up phase 
to assess severe side effects was built into most clinical 
trials.83,85,86 Over 75,000 children were followed in these stud-
ies for 31–100 days but no increased risk of intussusception 
was found. In fact, across all studies, there were significantly 
fewer serious adverse events noted in the vaccine recipients 
compared with placebo recipients.83,86 In addition, a study in 
East Asia reported no difference in nongastrointestinal seri-
ous adverse events in vaccine vs placebo recipients.86
Lanzhou lamb
A live, attenuated oral rotavirus vaccine (LLV) was devel-
oped by the Lanzhou Institute of Biological Products. The 
vaccine was developed by passing a wild-type group A 
serotype G10P[12] lamb rotavirus through primary calf 
kidney cells. After 37 passages, the virus was subsequently 
tested in several clinical studies. In 2000, LLR vaccine was 
licensed by China Drug Inspection and Management Bureau 
using a one-dose oral schedule. It is currently licensed in 
China to be given to children aged 2 to 36 months, followed 
by yearly boosters.94 However, the vaccine is relatively 
expensive in China, costing $18.4 per dose; as a result, few 
children received more than one dose.95 Between 2001 and 
2008, approximately 10,000,000 doses were administered 
in China.94 The vaccine is not routinely being used under 
China’s national immunization program.
The strongest evidence for efficacy of LLV comes from 
a case control study in Guangzhou province comparing 838 
children aged 2 months to 5 years hospitalized with rotavirus 
infections to 838 matched community controls.95 This study 
demonstrated a 73.3% (95% CI: 61.2–81.6) efficacy of one 
dose of LLV against hospitalized rotavirus gastroenteritis. 
The efficacy was found to be higher in older children, with 
efficacy in 12–23 month olds found to be 80.9% (95% CI: 
65.4–89.4) compared with 60.0% (95% CI: 28.6–77.6) in 
2–11 month olds. This may be due in-part to older children 
receiving vaccine at a later date, resulting in booster effect 
on an already present wild-type rotavirus response. A larger 
efficacy trial done in 4,000 infants aged from 6 to 24 months 
showed an efficacy against all-cause rotavirus gastroenteritis 
of 78%.94 However, this study was not placebo controlled, and 
the results are not available in a peer-reviewed journal.
A nonrandomized cohort study in Guangzhou province 
in southern China following 102 vaccinated children and 
145 unvaccinated children aged 6 months to 3 years for a total 
of 6 months found 53% fewer cases of rotavirus gastroen-
teritis in vaccinated children.96 In addition, disease was less 
severe; the average duration of disease was reduced by 24% 
(P , 0.001). A study comparing 225 children with rotavirus 
disease, 34 previously vaccinated and 191 unvaccinated, 
found a reduced duration (P , 0.001), severity (P = 0.041), 
and risk of hospitalization (P = 0.022) in the rotavirus vac-
cinated group.97 Immunologic studies among children aged 
6–24 months before and after vaccination showed that LLR Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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induced neutralizing antibody against rotavirus of all the 
four G types ranging from 40% to 70%.94,98–100 However, these 
studies did not include non-vaccinated controls.
Available data suggests that there are no major safety 
concerns with LLR. Trials carried out in Beijing, Guangxi 
province, and Zhejiang province reported mild side effects, 
with 5.6%–8.2% of vaccinated children experiencing low-
grade fever and 0%–2.1% reporting high-grade fever.98–100 
There has been one case report of intussusception following 
vaccination with LLR.101 Appropriately powered studies to 
assess differences in intussusceptions rates in vaccinated vs 
unvaccinated children have yet to be reported.
LLR has never been tested in a randomized, placebo-
controlled phase III clinical trial,95 so the true efficacy of 
the vaccine is unknown. In all of the reported trials, the 
majority of children were vaccinated during or after the 
peak age for rotavirus disease. In China, 50% of rotavirus 
infections occur between the ages of 6 and 11 months.102 It 
is unknown whether vaccinated children had prior natural 
rotavirus infection, in which case LLV could be boosting an 
already present immune response. The efficacy of LLR in 
rotavirus-naive populations is unknown. Controlled studies in 
which children are vaccinated prior to peak age of rotavirus 
incidence are necessary to demonstrate its true efficacy and 
potential impact on rotavirus gastroenteritis.
vaccines under development
In India, two live, cell line-adapted human viruses obtained 
from asymptomatic neonatal strains (116E and I321) 
recently underwent early clinical evaluation.103 Candidates 
using both vaccines were shown to be safe, with adverse 
event rates not statistically different in the vaccinated vs 
placebo groups. 116E, a predominately human vaccine 
strain of serotype G9P[11], with the VP4 appearing to be a 
natural reassortant from a bovine strain of rotavirus, seems 
to be more promising. Immunologic evaluation showed a 
73% serum IgA conversion rate compared with 20% in the 
  placebo group. I321 was less immunogenic, resulting in 39% 
  seroconversion. A subsequent immunogenicity study of 116E 
in 93 and 91 children receiving 104 and 105 focus-forming 
units of vaccine virus, respectively, were compared with 
184 placebo recipients.104 There was a $4-fold increase in 
antirotavirus IgA titers in 66.7% of children receiving the 
lower dose and 62.1% of children receiving the higher dose 
after the first dose compared with 18% of placébo recipients. 
After 3 doses, 64.5% of infants receiving the lower dose 
and 89.7% of those receiving the higher dose had a $4-fold 
increase in IgA compared with 25% of placebo recipients. 
No increase in adverse events was found between vaccine 
and placebo recipients. This vaccine is scheduled to begin 
phase III efficacy trials in late 2010.
Early rotavirus vaccine development studies are under-
way in Vietnam in an effort to produce inexpensive rotavirus 
vaccine locally. Three human rotavirus strains (genotypes 
G1P[8], G1P[4], and G4P[6]) have been characterized for 
potential use in a live attenuated vaccine.105 The wild-type 
viruses for these strains have been passed more than 30 times, 
each through cell culture with the goal of developing an 
  effective indigenously produced vaccine. The results of 
clinical trials are not yet available.
Additional considerations
Special populations
As a part of the RV5 REST trial, 2,070 preterm infants 
(gestational age, 25–36 weeks; median age, 34 weeks) were 
evaluated in a substudy.106 Vaccine efficacy was 73.0% (95% 
CI: −2.2 to 95.2) against all rotavirus gastroenteritis for the 
first season of follow-up, indicating that prematurity does 
not drastically reduce vaccine effectiveness.
There is some concern about vaccine-associated rotavirus 
disease occurring in immunocompromised individuals. There 
was a report of vaccine-acquired rotavirus disease following 
RV5 administration in three infants with severe combined 
  immunodeficiency (SCID); RV5 is now contraindicated 
in children with SCID.107 Further studies are needed to 
  determine the safety and efficacy of both RV1 and RV5 in 
severely   immunocompromised individuals. The effect of 
vaccination in HIV infected infants was studied in the RV1 
clinical trials. A substudy of the trial in South Africa showed 
that there was no increase in mortality in HIV-positive vaccine 
recipients and no difference in adverse events.108
viral shedding
For RV5, during REST and other phase III studies, potential 
fecal shedding between 4 and 6 days after each dose was 
monitored in nearly 250 children. In the 4- to 6-day period 
after the first dose, 8.9% of 360 RV5 recipients had detect-
able shedding by plaque assay of vaccine strains after the 
first dose. No shedding was detected after the second or third 
doses in vaccine recipients.109
For RV1, viral shedding was evaluated in early clinical 
trials.81,110,111 In one study of 213 infants, vaccine-type virus 
was shed in 28% of vaccine recipients 3 weeks after first 
immunization.82 After the second dose of vaccine, the propor-
tion of shedding after 3 weeks was only 5%. Studies of the 
concentration of vaccine virus in phase I and III trials have Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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ranged from 104 to 106.4 plaque-forming units of vaccine virus 
to placebo.80 For both RV1 and RV5, the potential for disease 
transmission from viral shedding remains unclear.
Breastfeeding
Preliminary evidence suggests that the efficacy of RV5 does 
not appear to be adversely affected by breastfeeding. The 
  efficacy, assessed retrospectively from a cohort from the 
REST trial, against all rotavirus gastroenteritis for infants 
never breastfed, sometimes breastfed, or exclusively breastfed 
was 68.3% (95% CI: 46.1–82.1), 82.2% (95% CI: 72.3–89.0), 
and 68.0% (95% CI: 53.8–78.3), respectively.112 Initial analy-
sis of RV1 suggested that exclusive breastfeeding resulted 
in a 10%–12% decrease in vaccine take; however, response 
remained high in all groups. The clinical significance of 
the slight difference in immune response with exclusive 
breastfeeding remains unclear.111 Further trials are needed to 
establish the relationship between breastfeeding and vaccine 
efficacy in a variety of developing country settings.
Concomitant administration  
with other vaccines
Clinical trials have shown that oral rotavirus vaccine admin-
istration does not affect the immunogenicity of routine 
injected vaccines.113 There has been a fear of reduced immune 
response to rotavirus vaccine when given together with oral 
polio vaccine (OPV). In a study of 735 healthy infants in 
Latin America, children were randomized to receive RV5 
concomitantly with OPV for 2 weeks prior to the OPV 
administration. Compared with staggered administration, 
the geometric mean titer of antirotavirus IgA was reduced by 
46% with concomitant administration. However, the IgA titer 
in the concomitant-use group increased by $3-fold between 
doses 1 and 3 in 93% of subjects, meeting the definition of 
noninferiority of immune response.114 For RV1, studies in 
South Africa and Bangladesh found no statistically significant 
difference in rotavirus IgA seroconversion rates when RV1 
was administered with and without OPV .115,116 Therefore, 
it appears that there is no contraindication to giving oral 
rotavirus vaccines simultaneously with OPV .
Dosing schedules
The rotavirus vaccine schedule is timed with other recom-
mended routine infant immunizations. RV5 is given at the 
same time as the primary diphtheria-tetanus-pertussis series, 
whereas RV1 is given with the first DTP dose, and either 
the 2nd or 3rd dose, depending on the country.117 The CDC 
and WHO recommend that the first dose be given between 
the ages of 6 and 15 weeks and final dose be given by 32 
weeks due to a lack of safety and efficacy data outside this 
age range.71,118 In developing countries, a significant number 
of children receive their primary DTP series outside these 
age ranges.119 Catch-up campaigns in older children are a 
common strategy for rapidly reducing disease burden in 
newly vaccinated populations and maintaining coverage in 
children missed during routine immunization.120,121 Due to 
lack of safety data in older children, no catch-up campaigns 
have been attempted with rotavirus vaccines. Additional 
research on safety is needed in children immunized outside 
of the recommended age range to inform scheduling.
The long-term immunogenicity of rotavirus vaccine is 
unknown or is the effect of reduced transmission on the 
maintenance of immunity in older children and adults. In this 
sense, it is not known if a booster dose is needed to main-
tain protective immunity, however observations of reduced 
efficacy in older infants suggest protection, may wane.85,90 
Ongoing longitudinal surveillance in recently introduced 
countries is necessary to determine long-term control strate-
gies once infant disease is controlled.
Serotype shift/replacement
Rotavirus shows considerable geographic and temporal 
  variation in serotypes.122,123 In addition, wild-type reassort-
ments continually occur and have the potential to affect 
clinical disease.14 Because of this natural variance and the 
relatively short time period in which rotavirus vaccines 
have been in routine use, it is not yet clear of the impact 
that routine vaccination will have on the serotype profile 
of disease-causing rotavirus strains, and whether serotype 
replacement will occur over time. Although some studies 
have suggested a change in serotype profile following vac-
cine introduction, it is not clear whether this change is due 
to vaccination or part of the normal serotype variation seen 
with rotavirus disease.124 Ongoing surveillance is needed in 
both developed and developing country settings to assess the 
affect of routine vaccination on the changing serotype profile 
and what serotypes are responsible for human disease.14
Relative effectiveness of Rv1 and Rv5
The difference in efficacy and effectiveness between RV1 
and RV5 has not been studied in a head-to-head clinical trial 
but appear to be similar based upon reported effect against 
severe rotavirus disease from single-vaccine clinical trials. In 
addition, the efficacies of both RV1 and RV5 against severe 
rotavirus disease vary depending on the income status of the 
countries that hosted the studies (Figure 1). Although overlap Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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exists between the efficacies estimated for each income 
group, and estimates likely vary based on the definition of 
severe gastroenteritis and length of follow-up, the overall 
trend is apparent; rotavirus vaccines are less effective in 
lower income settings. Lower efficacy in low-income set-
tings is likely a combination of poor immunological response 
caused by malnutrition, other intestinal infections, and 
immunosuppression efficacy against other oral vaccines, as 
has been seen with the OPV .125 Across the listed studies, 
the average efficacy for high, upper middle, lower middle, 
and low income countries are 90%, 85%, 66%, and 55%, 
respectively.70,71,75,76,83–87,89,92,93,126
Updated global estimations  
of rotavirus mortality
The most recent global estimations for rotavirus mortality 
were calculated based on child diarrheal mortality figures 
from 2004.3 However, the Child Health Epidemiology Ref-
erence Group at the WHO recently released data showing a 
substantial decline in global diarrheal morality.127 To update 
global rotavirus morality estimates, we followed the meth-
odology described by Parashar et al3 using 2008 country-
level estimations of the number of deaths due to diarrhea 
in children aged younger than 5 years in 2008.127 The use of 
rotavirus vaccine was controlled in countries who introduced 
rotavirus vaccine prior to 2008 by reducing the proportion of 
diarrhea caused by rotavirus based on the rotavirus immuni-
zation   coverage in 2008 or national estimates for coverage 
of three doses of diphtheria, pertussis, and tetanus vaccine 
(DTP-3) if rotavirus estimations were not available.117
Rates of deaths based on national income status (Table 2), 
region (Table 3), and national levels (Figures 2 and 3) are 
provided. In 2008, rotavirus was responsible for nearly 
400,000 deaths (Table 2) or the deaths of approximately 
4% of all children aged younger than 5 years. Varying the 
regional proportion of diarrheal deaths caused by rotavirus to 
the extreme estimates provided by Parashar et al3 gives low 
and high estimates of 320,000 and 440,000 deaths. As with 
previous estimates, the vast majority of deaths occur in low 
and lower middle income countries (Tables 2 and 3). Nine 
countries in Africa and Asia had more than 10,000 childhood 
rotavirus deaths in 2008 (Figure 2) while 30 countries had 
an incidence of rotavirus death greater than 100 per 100,000 
children aged younger than 5 years (Figure 3).
Potential impact of rotavirus  
vaccination on diarrheal mortality
By applying the average efficacies from national income status 
to the regional rotavirus mortality and hospitalization estimates 
calculated by Parashar et al3 and to the country-level DTP-3 
coverage in 2008,128 we are able to estimate the potential impact 
of rotavirus vaccine. Country-level reductions were summed to 
predict the potential impact of the vaccines on rotavirus deaths 
and rates of deaths based on national income status (Table 4), 
region (Table 5), and national levels (Figures 4–6).
The potential impact of rotavirus vaccines is striking. If 
rotavirus vaccines were introduced at the current coverage 
of DTP-3, it would prevent approximately 166,000 deaths 
in children aged younger than 5 years each year globally 
(Table 4). Varying the regional proportion of diarrheal deaths 
caused by rotavirus to the extreme estimates provided by 
Parashar et al3 gives low and high estimates of 137,000 and 
190,000 deaths prevented. Rotavirus vaccine is most effective 
in high-income countries, preventing approximately 71% of 
rotavirus deaths and 26% of diarrheal deaths. The two most 
populous upper middle income countries, Brazil and Mexico, 
already introduced rotavirus vaccines by 2008. However, in 
upper middle income countries that have not yet introduced 
the vaccine, it would prevent 64% and 21% of rotavirus and 
diarrheal deaths. Vaccination at current DTP-3 levels in low 
and lower middle income countries would prevent less than 
45% and 12% of rotavirus and diarrheal deaths, respectively, 
due to low efficacy and poor vaccine coverage in many coun-
tries. However, due to the large burden of diarrhea deaths in 
Table 2 Deaths due to rotavirus in children aged younger than 
5 years, stratified by national income stratum
Income 
classificationa
Total Per 100,000 
children younger 
than 5 y
High 413 0.6
Upper middle 5,330 6.9
Lower middle 191,264 53.4
Low 189,106 137.9
Total 386,113 209.7
Table 3 Deaths due to rotavirus in children aged younger than 
5 years, stratified by region
World bank Rotavirus deaths
Region Total Per 100,000 children 
younger than 5 y
Africa 236,519 155.8
Asia 144,095 39.6
europe 167 0.4
Latin America 
and Caribbean
5,000 8.8
North America 3 0.0
Oceania 328 11.6Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Universal introduction
prior to 2008
Figure 2 estimated distribution of deaths caused by rotavirus diarrhea among children aged younger than 5 years.
these countries and large birth cohorts, 98% of preventable 
rotavirus deaths occur in low and lower middle income 
countries. Similarly, the highest incidence of preventable 
deaths is also seen in lower income countries. The number 
of preventable rotavirus deaths per 100,000 children in 
low-income countries is over 100 times than that seen in 
high-income countries.
Regionally, the potential impact of for rotavirus is high-
est in Africa and Asia, where 99% of preventable rotavirus 
deaths occur, which also have the higher incidence of 
  preventable disease (Table 3). The highest absolute numbers 
of preventable deaths occur in the large, populous countries, 
such as India, Nigeria, the Democratic Republic of the Congo, 
Afghanistan, and Ethiopia (Figure 2), which account for 81,000 
(49%) of preventable deaths, in which India alone accounts 
for 16% of preventable deaths. Globally, 26 countries would 
prevent .50 deaths per 100,000 children younger than 5 years 
if rotavirus vaccine was introduced (Figure 3), with the majority 
of high-incidence countries located in Sub-Saharan Africa. Such 
a substantial reduction in deaths would go a long way towards 
helping countries to reach the Millennium Development Goal 4 
of reducing child mortality.
Death per 100,00
≥100
50–100
10–50
1–10
<1
Figure 3 estimated incidence of deaths caused by rotavirus diarrhea per 100,000 children aged younger than 5 years. Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Although vaccine efficacy is lower in low-income 
  settings, poor routine vaccination coverage reduces the 
potential impact of rotavirus vacation substantially. If vaccina-
tion with rotavirus reached 100% of children, 237,000 deaths 
(children aged younger than 5 years, would be averted each 
year; an additional 71,000 deaths averted compared with those 
using current DTP-3 coverage. In some countries, poor vaccine 
converge nearly negates the potential impact of rotavirus vac-
cines. In Chad, eg, the WHO estimates that only 20% of children 
received DTP-3 in 2008; combined with the efficacy seen in 
low-income countries, only 11% of rotavirus cases would be 
prevented. Similarly, many countries with high number of 
deaths due to rotavirus have poor vaccine coverage. India, 
which has a national DTP-3 coverage of 66%, could prevent 
an additional 14,000 rotavirus deaths. Clearly, strengthening 
routine immunization is critical to maximize the impact of any 
new vaccine and ensure   protection with traditional childhood 
immunization.
There are several reasons to believe that the estimations 
provided here are not entirely accurate. Parashar et al3 noted that 
more recent studies show a higher proportion of severe diarrhea 
caused by rotavirus in low-income countries compared with 
older studies, suggesting an underestimate in the proportion 
of diarrheal deaths caused by rotavirus. RV1 is administered 
following a two-dose schedule, so DTP-3 coverage estima-
tions would underestimate impact for any country using RV1. 
Both RV1 and RV5 provide some protection with incomplete 
vaccination and as a result, the proportion of disease prevented 
would be higher in developing countries where a substantial 
number of children are only partially immunized.128 On the 
contrary, many developed countries have substantial delays 
in infant immunization,119 which would miss early rotavirus 
cases and reduce impact. Efficacy estimations do not include 
herd effects of   immunization, which have been suggested to 
increase efficacy by 13%–25%.129
Conclusion
Rotavirus is the leading cause of diarrheal morbidity and 
mortality globally, with nearly every child being infected in 
early childhood. Updated estimates indicate that over 380,000 
rotavirus deaths occurred in 2008. Although treatment strate-
gies exist, most deaths occur in settings where access to care is 
limited. Preventative strategies are limited, and sanitation-based 
strategies are not effective at preventing the spread of the virus. 
As a result, several rotavirus vaccines have been developed 
from animal, human, and hybrid strains. Two rotavirus vac-
cines have been licensed and used internationally, with several 
others being developed. Of the licensed vaccines, clinical trials 
have demonstrated excellent efficacy, although has generally 
been lower in low-income settings. Introductions with both 
the licensed vaccines have been promising and have shown an 
impact on rotavirus and all-cause diarrhea in both high-income 
and low-income settings. Using estimations of rotavirus and 
current immunization levels, rotavirus vaccine would prevent 
Table 4 Impact of rotavirus vaccines on diarrheal deaths if introduced at level of DTP-3, stratified by national income stratum
Income 
classificationa
Diarrheal deaths prevented Proportion prevented
Total Per 100,000 children  
younger than 5 y
Rotavirus 
deaths, %
Diarrheal 
deaths, %
High 301 0.5 71 26
Upper middle 3,121 4.0 44 15
Lower middle 84,989 23.7 44 13
Low 77,417 56.5 41 12
Total 165,828 26.0 43 14
Note: aWorld Bank 2008 classification. GNP per capita estimations from the US Government131 were used to approximate GNi for the Cook islands, Nauru, Niue, and 
Tuvalu.
Table 5 Impact of rotavirus vaccines on diarrheal deaths if introduced at level of DTP-3, stratified by regiona
World Bank 
Region
Diarrheal deaths prevented Proportion prevented
Total Per 100,000 children aged 
younger than 5 years
Rotavirus 
deaths, %
Diarrheal 
deaths, %
Africa 95,623 63.0 40 12
Asia 67,803 18.6 47 14
europe 136 0.4 80 31
Latin America 
and Caribbean
2,145 3.8 31 11
Oceania 121 4.3 37 15
Note: aNorth America has not been included because rotavirus vaccines were already reaching 88% of the children in the region.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Figure 4 Total deaths prevented by rotavirus vaccine in children aged under 5 years if introduced at level of DTP-3.
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Figure 5 Total deaths prevented by rotavirus vaccine per 100,000 children aged younger than 5 years if introduced at level of DTP-3.
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over 160,000 deaths yearly if introduced on a global level. 
The largest impact on mortality would be seen in low-income 
and middle-income countries, despite poor immunization 
coverage and lower efficacy. Thanks to international efforts, 
vaccine introduction is progressing in both high-income and 
low-income settings. However, focused efforts are needed on 
large, highest burden countries if rotavirus mortality is to be 
reduced dramatically.
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